First Trust Advisors
CRNX

First Trust Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

First Trust Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.37M Buy
63,352
+11,987
+23% +$446K ﹤0.01% 1935
2026
Q1 		$1.87M Buy
51,365
+18,215
+55% +$814K ﹤0.01% 1946
2025
Q4 		$1.54M Buy
33,150
+26,219
+378% +$1.17M ﹤0.01% 1993
2025
Q3 		$289K Sell
6,931
-72
-1% -$2.3K ﹤0.01% 2419
2025
Q2 		$201K Sell
7,003
-30,755
-81% -$950K ﹤0.01% 2525
2025
Q1 		$1.27M Sell
37,758
-158,063
-81% -$5.9M ﹤0.01% 1966
2024
Q4 		$10M Sell
195,821
-14,570
-7% -$815K 0.01% 1058
2024
Q3 		$10.8M Buy
210,391
+13,430
+7% +$693K 0.01% 1020
2024
Q2 		$8.82M Buy
196,961
+95,224
+94% +$4.4M 0.01% 1060
2024
Q1 		$4.76M Buy
101,737
+28,280
+38% +$1.11M ﹤0.01% 1313
2023
Q4 		$2.61M Buy
+73,457
New +$2.25M ﹤0.01% 1604

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Trust Advisors's CRNX Position: Q2 2026 in Review

First Trust Advisors increased its Crinetics Pharmaceuticals (CRNX) stake by 23% in Q2 2026, buying an estimated $446K and bringing the position to 63,352 shares worth $2.37M. The position accounts for ﹤0.01% of the portfolio, ranked #1935.

First Trust Advisors first reported a position in CRNX in Q4 2023 and has held it in 11 quarters since. The position peaked at $10.8M in Q3 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • First Trust Advisors held 63,352 shares of Crinetics Pharmaceuticals worth $2.37M as of Q2 2026.
  • First Trust Advisors bought 11,987 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $446K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of First Trust Advisors's portfolio in Q2 2026, its #1935 holding.
  • First Trust Advisors first reported a position in Crinetics Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • First Trust Advisors's Crinetics Pharmaceuticals position peaked at $10.8M in Q3 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.